Alphagenics Inc

Protein Potential LLC is a company based in Rockville, MD, dedicated to providing comprehensive information and resources related to protein and its various applications. Their focus is on delivering relevant links and insights across all topics associated with protein potential. With an emphasis on quality content, Protein Potential LLC aims to be a go-to source for individuals interested in exploring the benefits and uses of protein in various contexts. The company is committed to ensuring that all information is protected under copyright, maintaining a strong privacy policy for its users. Generated from the website

Sanaria Inc. is a biotechnology company dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Plasmodium falciparum malaria is responsible for more childhood mortality than any other single infectious agent. The firm s vaccine development efforts are focused on African children, the population most urgently in need of protection. Based in Rockville, Md., it houses a custom-designed and constructed dedicated clinical manufacturing facility for producing its attenuated malaria parasite vaccine. Sanaria Inc. has two ongoing Cooperative Research and Development Agreements (CRADAs) with U.S. government laboratories, a development contract with a biotechnology company, a funded research agreement with a nonprofit, and a services agreement with a nonprofit research institute and a government laboratory.

Immunomic Therapeutics Inc. is a privately held clinical stage biotechnology company based in Rockville, MD, focused on pioneering nucleic acid immunotherapy platforms. Utilizing their proprietary UNiversal Intracellular Targeted Expression (UNITE) technology, the company aims to develop vaccines that elicit broad immune responses to treat various conditions, with a primary concentration in oncology. The company's ongoing pipeline includes several innovative therapeutic vaccines under development for cancers such as glioblastoma multiforme and triple-negative breast cancer, as well as initiatives addressing infectious diseases and allergies. Through its investigational technologies, Immunomic Therapeutics strives to improve patient health outcomes and extend lives by harnessing the body's natural immune mechanisms. Generated from the website